This study compared the effects of multiple daily injection therapy (MDI) on glycemic variability in a real fasting with CGM technology in real- life condition of patients with type 1 diabetes (T1D).
This was a paralell trial in 47 T1D patients, with a mean age of 34 years, and glycosilated haemoglobin (HbA1c) level of 8.50%; 31 patients were treated MDI with glargina-100, 10 with detemir, 6 with degludec). We analyzed the patients in three groups of HbA1c, <7.5% (N=17), 7.5-8-8.8% (N=15) and >8.8% (N=15). We used CGM by evaluated the coefficient of variation (CV) and mean amplitude of glycemic excursions (MAGE), we defined real fasting before three hours to breakfast and real posprandial state by rest of day.
The primary end point was the change of CV and MAGE in real fasting. Secondary end points included CV and MAGE in posprandial state. We compared different subgroups of basal HbA1c and insulin basal therapy.
the HbA1c was different (6.86±0.14 vs 8.24±0.10 vs 10.28±0.30; p=0.001).However we didn’t found differences between the groups respect to CV-fasting (28.65±2.53 vs 37.39±4.17 vs 30.81±2.73; p=0.14) and MAGE-fasting (162.70±24.25 vs 158.93±23.40 vs 135.60±22.84; p=0.68). We found the only significant differences in analysis of subgroups with MAGE-posprandial state (77.58±12.92 vs 83.66±13.27 vs 128.93±17.36; p=0.034). We didn’t found any differences in analysis of subgroups with different insulin basal therapy
In T1D patients under clinical practice conditions, subgroups Of HbA1c or insulin basal therapy were not different regarding glycemic variability in a real fasting period.